Generic Semaglutide (Oral)
Type 2 Diabetes, Obesity
DevelopmentTargeted launch FY27
Key Facts
Indication
Type 2 Diabetes, Obesity
Phase
Development
Status
Targeted launch FY27
Company
About Dr. Reddy's Laboratories
Founded in 1984, Dr. Reddy's Laboratories has evolved from an API manufacturer into a global pharmaceutical leader with a mission to accelerate access to affordable and innovative medicines. Its core strategy balances a robust generics and biosimilars business with targeted investments in complex generics, innovative therapies, and strategic partnerships. Key recent achievements include the first-to-market launch of a generic semaglutide injection in India, expansion of its biosimilar portfolio in developed markets, and a stated goal to touch 1.5 billion patient lives by 2030.
View full company profileTherapeutic Areas
Other Type 2 Diabetes, Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Semaglutide Injection | Lupin | Market |
| GLP-1 Agonist Program | Biolingus | Pre-clinical |
| GLP-1 Receptor Agonist (Gan & Lee) | Lupin Limited | Clinical Development |
| Semaglutide (Oral Generic) | Dr. Reddy's Laboratories | Pre-launch |